What is Personalis?
Founded in 2011 and headquartered in Menlo Park, California, Personalis provides advanced genomic sequencing and analytic solutions. The company occupies a critical niche in the precision medicine market, enabling the development of personalized cancer vaccines and immunotherapies through high-fidelity molecular data. By integrating complex genomic insights with clinical data, Personalis empowers researchers and clinicians to move beyond traditional treatment paradigms, facilitating a more tailored approach to oncology. Its market position is defined by its ability to bridge the gap between raw sequencing data and actionable therapeutic intelligence, a capability that has attracted significant institutional backing since its inception.
How much funding has Personalis raised?
Personalis has raised a total of $233.5M across 5 funding rounds:
Series A
$20M
Series B
$22M
Series C
$33M
Stock Offering
$140.8M
Stock Offering
$17.7M
Series A (2011): $20M with participation from Stanford University, Mohr Davidow Ventures, Abingworth, and Lightspeed Venture Partners
Series B (2013): $22M led by Wellington Shields & Co., Mohr Davidow Ventures, Abingworth, and Lightspeed Venture Partners
Series C (2015): $33M supported by Abingworth, Lightspeed Venture Partners, and Mohr Davidow Ventures
Stock Issuance/Offering (2019): $140.8M, investors not publicly disclosed
Stock Issuance/Offering (2024): $17.7M backed by Tempus
Key Investors in Personalis
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that transforms cutting-edge science into novel medicines by providing capital and expertise to top-tier management teams.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage venture capital firm that invests in early and growth-stage technology companies across sectors including enterprise software and infrastructure.
Tempus
Tempus AI is a technology company operating at the intersection of artificial intelligence and clinical data science, focused on transforming oncology and cardiology through precision medicine.
What's next for Personalis?
With the infusion of recent capital, Personalis is well-positioned to accelerate its strategic roadmap, focusing on the expansion of its clinical data engine and the refinement of its predictive modeling capabilities. The company is expected to leverage these resources to deepen its integration within the healthcare ecosystem, particularly in the realms of oncology and immunotherapy. As the firm transitions into its next phase of growth, the focus will likely shift toward scaling its laboratory operations and enhancing its software platform to meet the increasing demand for precision-based therapeutic models. The ongoing collaboration with industry leaders and the continued refinement of its data-driven diagnostic tools suggest a trajectory aimed at solidifying its leadership in the competitive landscape of genomic diagnostics.
See full Personalis company page
